Mesna Injection, Solution
NDC Package 10019-951-05

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Mesna injection is a medication used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamide. This formulation utilizes a injection, solution delivery system. Marketed by Baxter Healthcare Company, this product is identified by NDC 10019-951 and is authorized under FDA application NDA019884.

Identification & Billing

NDC Package Code
10019-951-05
Package Description
1 VIAL in 1 BOX / 10 mL in 1 VIAL (10019-951-10)
Product Code
10019-951
11-Digit Billing Format
10019095105
Billing Unit
C112160
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Mesna
Non-Proprietary Name
Mesna
Substance Name
Mesna
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
MESNA 100 mg/mL
Pharmacologic Class
Cytoprotective Agent - [EPC] (Established Pharmacologic Class)
Usage Information
This medication is used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamide. Mesna helps to protect the lining of the bladder against damage from ifosfamide. The body breaks down ifosfamide to form a product that can harm the bladder, and mesna works by making this product less harmful. However, mesna does not change ifosfamide's anti-cancer effects.

Regulatory & Marketing

Labeler Name
Baxter Healthcare Company
Product Type
Human Prescription Drug
FDA Application #
NDA019884
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-30-1988
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J9209
Source: PDAC
INJECTION, MESNA, 200 MG
HCPCS Dosage 200 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10019-951-05 identifies a specific commercial package of 1 vial in 1 box / 10 ml in 1 vial (10019-951-10) of Mesna, a human prescription drug labeled by Baxter Healthcare Company. This injection, solution is formulated for intravenous use and contains mesna as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Company on December 30, 1988. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamide. Mesna helps to protect the lining of the bladder against damage from ifosfamide. The body breaks down ifosfamide to form a product that can harm the bladder, and mesna works by making this product less harmful. However, mesna does not change ifosfamide's anti-cancer effects.

How is this Baxter Healthcare Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10019095105. Quantities are measured in C112160. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
10019-951-05
11-Digit CMS (5-4-2)
10019-0951-05

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.